Business wire
Expanded footprint to 1,700 hospitals and healthcare systems cements leadership in AI-powered care coordination
Viz.ai Secures New Partnerships with Three Global Pharmaceutical Companies as Growth in Hospital Footprint Expands to 60,000 Providers
Media Contact
Brendi Bluitt
brendi.bluitt@finnpartners.com
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced significant milestones in its mission to transform healthcare delivery. In 2024, the company forged new partnerships with three of the largest, global pharmaceutical companies in the world, realizing a total of 10 partnerships with leading life science companies. Viz.ai expanded its reach to serve 1,700 hospitals with a broad user base that grew by more than 30% to reach 60,000 healthcare providers in the United States. This rapidly growing footprint, driven by new product innovation and real-world evidence, demonstrates the company’s commitment to increase access to life-saving treatments.
“This year has surpassed our expectations as Viz.ai’s footprint in healthcare continued to grow with the majority of the 50 largest healthcare systems in the U.S. adopting our platform,” said Dr. Chris Mansi, CEO and co-founder at Viz.ai. “This reaffirms Viz.ai’s position as the leading, trusted AI-powered platform and our dedication to delivering tools that empower providers, streamline workflows and improve patient outcomes. As we continue to broaden our patient impact with leading life science collaborators and healthcare systems, we look to accelerate better patient care by leveraging AI-driven insights and care coordination in 2025.”
In 2024, Viz.ai introduced new products and capabilities to its Viz.ai One™ enterprise platform, which now includes more than 48 clinical AI modules. Key innovations include the introduction of the Viz ICH Plus™ algorithm for automated volumetric assessment and cutting-edge 3D CT angiography functionality, as well as the launch of Viz Connect® for cryptogenic stroke and Viz ACS for acute coronary syndrome. These enhancements further strengthen Viz.ai’s offering in cardiovascular and neurovascular care pathways, enhancing functionality in both acute and non-acute treatment scenarios and underscoring the company’s commitment to transform healthcare through AI-driven solutions.
With 24 new clinical studies this year and more than 100 clinical publications and abstracts to date, Viz.ai has continued to demonstrate substantial real-world evidence of the positive impact of its AI-powered care coordination on patient outcomes and economic efficiency. Three studies at the American College of Cardiology Scientific Session 2024 demonstrated the positive impact of Viz.ai’s hypertrophic cardiomyopathy module on suspected disease detection and patient triage for improved care. Another recent study on pulmonary embolism (PE) showed that the Viz PE solution significantly improved time to assessment and time to anticoagulation with a 74% reduction in in-hospital mortality risk. Additionally, six studies presented at the International Stroke Conference (ISC) 2024 showed the real-world impact of Viz.ai on positive outcomes in clinical practice for acute ischemic stroke, cryptogenic stroke, unruptured incidental cerebral aneurysms and brain hemorrhage.
Viz.ai formed new partnerships with leading healthcare technology organizations to further scale its impact. At the Radiological Society of North America (RSNA) meeting, Viz.ai announced a collaboration with Microsoft to deliver a comprehensive platform of more than 48 diagnostic imaging AI models seamlessly embedded into clinical workflows. Together, Viz.ai and Microsoft aim to help radiologists create more accurate reports more efficiently, streamline communication to treating physicians, and support care team collaboration for appropriate follow-up and treatment for patients. Viz.ai announced a partnership with Cleerly at the American College of Cardiology meeting (ACC) and a partnership with Addario Lung Cancer Medical Institute at the American Society of Clinical Oncology meeting to advance care across cardiology, oncology and neurology.
This past year, Viz.ai was recognized by Fast Company’s 50 Most Innovative Companies list, received the Prix Galien Award for Best Digital Health Solution in Pharma, and earned its second Edison Award for Viz Pulmonary Embolism. Viz.ai CEO Dr Chris Mansi was also featured as one of the 100 most influential people in AI by TIME Magazine. Collectively, these honors reflect the company’s innovation and impact on expanding patient access to life-saving treatments.
About Viz.ai
Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,700 hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai One™ is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250107173102/en/
